Prime Medicine (PRME) Other financing activities (2022 - 2026)
Prime Medicine's (PRME) quarterly Other financing activities came in at $393000.0 in Q1 2026, down 49.68% on a QoQ basis from $781000.0 in Q4 2025.
Prime Medicine (PRME) Other financing activities (2022 - 2026) Analysis & Trends
Prime Medicine (PRME) has 5 years of Other financing activities data on file, last reported at $393000.0 in Q1 2026.
- Quarterly Other financing activities changed N/A year-over-year to $393000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 93.33% YoY) and the FY2025 annual result came in at $781000.0, down 95.85% from the prior year.
- Other financing activities eased to $393000.0 in Q1 2026, from $781000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $17.6 million in Q2 2024 to a low of -$68000.0 in Q2 2023.
- A 5-year average of $2.1 million and a median of $293500.0 in 2023 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2023 — Other financing activities gained 24.36% — and 2024, when it jumped 25982.35%.
- Tracing PRME's Other financing activities over 5 years: stood at $156000.0 in 2022, then advanced by 24.36% to $194000.0 in 2023, then jumped by 8972.16% to $17.6 million in 2024, then slumped by 95.56% to $781000.0 in 2025, then slumped by 49.68% to $393000.0 in 2026.
- The last three Other financing activities figures came in at $393000.0 (Q1 2026), $781000.0 (Q4 2025), and $17.6 million (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23,000.00 |
| Jun 30, 2026 | 23,000.00 |
| Mar 31, 2026 | 393,000.00 |
| Mar 31, 2026 | 393,000.00 |
| Dec 31, 2025 | 781,000.00 |
| Dec 31, 2025 | 781,000.00 |
| Jun 30, 2024 | 17.60 Mn |
| Jun 30, 2024 | 17.60 Mn |
| Mar 31, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.20 Mn |
| Dec 31, 2023 | 194,000.00 |
| Dec 31, 2023 | 194,000.00 |
| Sep 30, 2023 | 461,000.00 |
| Sep 30, 2023 | 461,000.00 |
| Jun 30, 2023 | -68,000.00 |
| Jun 30, 2023 | -68,000.00 |
| Mar 31, 2023 | 68,000.00 |
| Mar 31, 2023 | 68,000.00 |
| Dec 31, 2022 | 156,000.00 |
| Dec 31, 2022 | 156,000.00 |